Angiogenesis inhibitors in early development for gastric cancer

Area of Science:

• Oncology
• Vascular Biology
• Pharmacology

Background:

• Angiogenesis is vital for tumor growth, making it a key therapeutic target.
• Various drug classes, including VEGF inhibitors, TKIs, IMiDs, and mTOR inhibitors, exhibit antiangiogenic properties.
• Gastric cancer (GC) research extensively explores antiangiogenic strategies.

Purpose of the Study:

• To review the efficacy of antiangiogenic compounds in preclinical and clinical gastric cancer settings.
• To discuss the future of angiogenesis as a therapeutic target in GC.
• To present a model for combining ramucirumab with immunotherapy.

Main Methods:

• Review of preclinical and clinical studies on antiangiogenic agents in gastric cancer.
• Analysis of existing therapeutic strategies and emerging treatment modalities.
• Discussion of novel approaches including nanotechnology and molecular subtyping.

Main Results:

• Ramucirumab, a VEGFR2 monoclonal antibody, is the most effective antiangiogenic agent in GC clinical studies to date.
• Ramucirumab is established as a second-line therapy for gastric cancer.
• Future research will likely involve combining targeted agents like ramucirumab with immune checkpoint inhibitors.

Conclusions:

• Angiogenesis remains a critical therapeutic target in gastric cancer.
• Ramucirumab represents a significant advancement in antiangiogenic therapy for GC.
• Combination therapies, precision medicine, and novel approaches like nanotechnology hold promise for future GC treatment.